Search Results

You are looking at 31 - 40 of 120 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

(undifferentiated) carcinoma of thyroid, with lymphovascular and perineural invasion that also involved the adjoining esophagus and jugular vein; 1 of 3 lymph nodes was positive for metastatic carcinoma. Two separate papillary thyroid microcarcinomas, 0.4 and 0.1 cm

Full access

Tanner M. Johanns, George Ansstas, and Sonika Dahiya

, 5 These observations, along with encouraging early-phase data in other histologies, such as papillary thyroid cancer 6 and hairy cell leukemia, 7 which both have high frequencies of BRAF V600E mutations, have led to increasing interest in

Full access

Presenter: Philippe E. Spiess

persistent disease, particularly in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk NMIBC specifically with carcinoma in situ with or without papillary bladder tumors. Other topical issues in the field include recently standardized

Full access

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

(1) differentiated (including papillary, follicular, and Hürthle cell); (2) medullary (MTC); and (3) anaplastic (aggressive undifferentiated tumor). Of 55,554 patients diagnosed with thyroid carcinoma between 2007 and 2011, 88.0% had papillary

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

DM 2nd Gehrig PA Fader AN Olawaiye AB . Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review . Gynecol Oncol 2009 ; 115 : 142 – 153 . 181. Olawaiye AB Boruta DM 2nd . Management of

Full access

Center, New York, NY This is a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). Primary Outcome Measures

Full access

study to evaluate the efficacy of combination sorafenib and temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hürthle cell, anaplastic). Primary Outcome Measures: Determine the objective response

Full access

, IVC papillary thyroid cancer Institution: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium This phase I trial is studying the side effects and best dose of iodine I-131 ( 131 I) when given with pazopanib

Full access

Tatjana Gavrancic and Yeun-Hee Anna Park

prognosis. It is defined as an alpha fetoprotein (AFP)–producing primary lung carcinoma with pathologic findings of acinar and papillary adenocarcinoma resembling hepatocellular carcinoma (HCC). Globally, only 24 cases have been reported. This report

Full access

Maurie Markman

of residual disease after primary surgical cytoreduction, and, in the case of advanced disease, morphologic subtype (e.g., mucinous vs. papillary serous). Importantly, however, even if this prognostic information helps patients and physicians make